{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Mesothelioma&page=2", "query": { "condition": "Unresectable Mesothelioma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Mesothelioma&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Mesothelioma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T18:11:25.633Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02357147", "title": "Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma, Malignant" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Amatuximab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2015-11-03", "completion_date": "2018-11-30", "has_results": true, "last_update_posted_date": "2020-03-17", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 7, "location_summary": "La Jolla, California • Newark, Delaware • Bethesda, Maryland + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02357147" }, { "nct_id": "NCT05071014", "title": "A Study of Pembrolizumab and Cryoablation in People With Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Unresectable Mesothelioma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Image-guided cryoablation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-09-24", "completion_date": "2023-12-18", "has_results": false, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05071014" }, { "nct_id": "NCT01907100", "title": "Nintedanib (BIBF 1120) in Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 545, "start_date": "2013-09-19", "completion_date": "2018-08-31", "has_results": true, "last_update_posted_date": "2019-03-18", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 10, "location_summary": "Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01907100" }, { "nct_id": "NCT06051695", "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "NSCLC", "Non Small Cell Lung Cancer", "NSCLC, Recurrent", "Non-Small Cell Squamous Lung Cancer", "Pancreas Cancer", "Pancreatic Neoplasm", "Colorectal Adenocarcinoma", "CRC", "Colon Cancer", "Rectal Cancer", "Cancer", "Ovarian Cancer", "Ovarian Neoplasms", "Mesothelioma", "Mesothelioma, Malignant", "Ovary Cancer", "Lung Cancer", "MESOM" ], "interventions": [ { "name": "A2B694", "type": "BIOLOGICAL" }, { "name": "A2B543", "type": "BIOLOGICAL" }, { "name": "xT CDx with HLA-LOH Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 474, "start_date": "2024-04-03", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 12, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051695" }, { "nct_id": "NCT04670445", "title": "Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IV Melanoma", "Advanced Lung Cancer", "Stage IV Non-Small Cell Lung Cancer", "Unresectable Non-Small Cell Lung Carcinoma", "Unresectable Stage III Non-Small Cell Lung Cancer", "Small Cell Lung Cancer Extensive Stage", "Stage IV Merkel Cell Carcinoma", "Stage IV Cutaneous Squamous Cell Carcinoma", "Stage IV Basal Cell Carcinoma", "Stage IV Breast Cancer", "Stage IV Colorectal Cancer", "Stage IV Gastric Cancer", "Stage IV Esophageal Cancer", "Stage IV Hepatocellular Cancer", "Stage IV Renal Cell Carcinoma", "Stage IV Bladder Cancer", "Stage IV Head and Neck Squamous Cell Carcinoma", "Stage IV Cervical Cancer", "Stage IV Endometrial Cancer", "Stage IV Mesothelioma", "Immunotherapy", "Immune Checkpoint Inhibitors" ], "interventions": [ { "name": "Educational Video and QPL List", "type": "OTHER" }, { "name": "Usual Care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2021-01-23", "completion_date": "2024-04-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04670445" }, { "nct_id": "NCT06097728", "title": "MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable Pleural Mesothelioma" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 863, "start_date": "2023-11-09", "completion_date": "2028-11-16", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 14, "location_summary": "Santa Rosa, California • Aurora, Colorado • Jacksonville, Florida + 10 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06097728" }, { "nct_id": "NCT02661659", "title": "A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Pleural Mesothelioma (MPM)" ], "interventions": [ { "name": "Multipeptide vaccine S-588210", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-06-12", "completion_date": "2017-10-03", "has_results": false, "last_update_posted_date": "2018-05-14", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02661659" }, { "nct_id": "NCT02611037", "title": "Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma", "Mesothelioma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Lung Cancer Symptom Scale for Mesothelioma Questionnaire", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2016-03-04", "completion_date": "2024-01-26", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611037" }, { "nct_id": "NCT04334759", "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mesothelioma", "Pleural Mesothelioma", "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Standard Chemotherapy", "type": "DRUG" }, { "name": "Ipilimumab and Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 214, "start_date": "2021-02-18", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 25, "location_summary": "La Jolla, California • Miami, Florida • Tampa, Florida + 20 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04334759" }, { "nct_id": "NCT07126509", "title": "Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mesothelioma", "Mesothelioma; Lung", "Mesotheliomas Pleural", "Mesothelioma Malignant Advanced", "Mesothelioma, Malignant" ], "interventions": [ { "name": "Partial Pleurectomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-12-02", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-03T18:11:25.633Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07126509" } ] }